Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)

LJUDMILA STOJANOVICH
“Bezanijska kosa” University Medical Center, Belgrade University, Serbia

Abstract
The role of influenza vaccination in patients suffering from autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), has long been a subject of discussion. The risk of exacerbation of the main disease following vaccination is of particular concern, and needs to be carefully evaluated against the risk of disease flares as a result of infections. Our study included 69 SLE patients and 54 RA patients, all in stable condition. We split the groups into two subgroups each: patients in SLE1 (23 patients) and RA1 (23 patients) received the flu vaccine (“Vaxigrip”, Aventis Pasteur) in November 2003. Patients in SLE2 (46 patients) and RA2 (31 patients) were not vaccinated. Throughout the following year, we studied parameters of disease activity and the occurrence of viral respiratory and bacterial infections in our patients. The vaccine was well tolerated in all cases. Vaccinated patients had significantly fewer occurrences of infections. Every viral and bacterial infection resulted in the worsening of the main disease. We believe that influenza vaccine is indicated for SLE and RA patients in stable condition. However, this decision must be made on a patient-by-patient basis. We plan to continue our study with the goal of formulating a better protocol for the clinical practice.

Keywords: Influenza vaccination, rheumatoid arthritis, systemic lupus erythematosus, autoimmune diseases

Introduction
Vaccination against influenza is the primary strategy to reduce the mortality and morbidity associated with influenza. The vaccine is primarily recommended for persons at increased risk of severe influenza such as immunocompromised subjects, including patients with autoimmune diseases (Herron et al. 1979; Shoenfeld and Rose 2004).

The role of influenza vaccination in patients suffering from autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), has long been a subject of discussion (Nosal 2000). Etiology of autoimmune diseases is still unknown, and among others, two possible triggers are cited in the literature: infections and vaccination (Rose 1998; Sibilia and Maillefert 2002; Aron-Maor and Shoenfeld 2004). An infection can induce or trigger autoimmune disease (Doran et al. 2002; Glück et al. 2005). Viral infections have specifically been causally associated with SLE (Zandman-Goddard and Shoenfeld 2004), and there are documented cases of SLE presenting itself after vaccination (Shoenfeld and Rose 2004). However, it has also been documented that the swine-flu influenza vaccine was well tolerated in SLE and RA patients (Avery 1999; Stojanovich 2005; Del Porto et al. 2006), albeit with a lower response to immunization compared to healthy controls.

However, same case reports suggest an association between influenza vaccination and the development or exacerbation of chronic autoimmune disorders such as RA, SLE (Blumberg et al. 1980) and vasculitis (Iyngkaran et al. 2003).

Patients with autoimmune rheumatic diseases run twice as high a risk of infection compared to healthy controls (Doran et al. 2002). This is due in part to the immunoregulatory abnormalities associated with the disease itself, but also in large part to the immunosuppressive therapy administered to these patients in the interest of delaying joint destruction. The effect of disease-modifying therapies on the...
immune system may be quite dramatic, especially if some of the more aggressive protocols are administered that may lead to opportunistic infections otherwise only seen in patients with advanced HIV infection (Glück et al. 2005).

Materials and methods

Our study included 69 patients with SLE (mean age 44.74 ± 13.58) and 54 patients with RA (mean age 57.78 ± 12.42). We further split both groups into two subgroups each: subgroups SLE₁ (23 patients, 33.33%) and RA₁ (23 patients, 42.59%) included patients with SLE and RA, respectively, who received the flu vaccine (“Vaxigrip”, Aventis Pasteur). Subgroups SLE₂ (46 patients, 66.67%) and RA₂ (31 patients, 57.41%) were comprised of patients who were not vaccinated against flu. The two pairs of subgroups were comparable with respect to age, gender, disease activity, manifestations of the main disease, and other parameters (such as immunoserological parameters, etc.). Patients from groups SLE₁ and RA₁ were all vaccinated in November 2003. Throughout the following year, we studied parameters of disease activity (SLEDAI for SLE) and the occurrence of viral respiratory and bacterial infections in our patients.

Results

The vaccine was well tolerated by all patients in groups SLE₁ and RA₁. The following occurrences of viral respiratory and bacterial infections were registered in our patients: 1 (2.17%) patient from SLE₂ had pneumonia; 2 (8.7%) patients from SLE₁ and 17 (36.97%) patients from SLE₂ suffered from acute bronchitis that required antibiotic treatment. Various viral respiratory infections occurred significantly more often in SLE₂ compared to SLE₁, with \( p < 0.005 \). However, these infections also correlated with age (patients older than 30 years of age) with \( p = 0.04783 \). The occurrence of bacterial and viral respiratory infections in our SLE population is summarized in Table I. In no single case did we witness worsening of main disease after vaccination. Unfortunately, this was not the case in SLE₂, where primary symptoms of SLE worsened after treatments of viral and bacterial infections with statistical significance (\( p = 0.008 \)). A similar tendency was registered in patients with RA. No pneumonia occurred in either RA₁ or RA₂.

<table>
<thead>
<tr>
<th>Disease</th>
<th>SLE₁</th>
<th>SLE₂</th>
<th>RA₁</th>
<th>RA₂</th>
<th>( p )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumonia</td>
<td>0(0)</td>
<td>1(8.7)</td>
<td>0(0)</td>
<td>0(0)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Acute bronchitis</td>
<td>1(4.3)</td>
<td>17(36.9)</td>
<td>7(22.6)</td>
<td>&lt;0.05</td>
<td></td>
</tr>
<tr>
<td>Viral respiratory infections</td>
<td>5(21.7)</td>
<td>21(45.6)</td>
<td>19(61.3)</td>
<td>&lt;0.05</td>
<td></td>
</tr>
</tbody>
</table>

Table I. Systemic lupus erythematosus (SLE).

However, acute bronchitis that required antibiotic treatment was diagnosed in only 1 (4.35%) patient in RA₁, compared to 7 (22.58%) patients in RA₂. Various viral respiratory infections were seen in 2 (8.70%) patients in RA₁, compared to 19 (61.29%) patients in RA₂, a statistically significant difference (Table II). Every viral and bacterial infection in our autoimmune patients diseases resulted in the worsening of the main disease, and required a correction of immune-suppressants.

Discussion

It is important to note that infections are of particular concern to autoimmune patients (Shoenfeld and Rose 2004). Not only is the course of the main disease often adversely affected by the infection, but also cytostatic therapy has to be paused during that time, which may itself lead to exacerbation of the main disease (Fomin et al. 2006). To make matters worse, autoimmune patients receive long-term treatment with steroids and immunosuppressant, which makes them more susceptible to infections such as influenza.

The goal of our study is two-fold. On the one hand, we study the risks associated with vaccination by a modern influenza vaccine in SLE and RA patients in stable condition. Additionally, we analyse the dangers posed by viral respiratory and bacterial infections to these patients.

We have shown that vaccination against influenza was safe and generated a good humoral response in SLE and RA.

Although yearly influenza vaccination is now recommended for patients with RA, a paucity of long-term studies deal with the influence of repeated vaccination upon both the incidence and exacerbation of pre-existing systemic rheumatic diseases (Kurland et al. 1984; Gavaghan and Webber 1993). If a true increase in relative risk exists, albeit small, then an increased frequency of such complications might be anticipated. Although for the vast majority of patients the benefits of regular influenza vaccination will likely far exceed its potential risks, we still advise appropriate monitoring of individuals with known systemic rheumatic diseases, early reporting of suspected adverse events associated with vaccination, and consideration of large prospective studies to determine the actual risks of currently recommended vaccination protocols (Chalmers et al. 1994; Cimmino et al. 1995; Avery 1999).
Despite this recommendation, the uptake of vaccination in autoimmune patients is still sub-optimal, mostly because the patients have not been offered the vaccine. Reduced compliance with immunization against influenza is related to concerns about the vaccine’s safety for these patients. Our present results verify the safety of influenza vaccination in rheumatoid arthritis, confirming our own and other previous studies in SLE and RA, where patients did not experience significant clinical flares following vaccination.

The assessment of efficacy and safety of vaccination against the influenza virus in patients with rheumatoid arthritis must place special emphasis on the effect of disease-modifying anti-rheumatic drugs (DMARDs) such as tumor necrosis factor (TNF) blockers. The humoral response to influenza vaccination is not affected by the use of prednisone or DMARDs (Fomin et al. 2006).

Our study indicates that a modern influenza vaccine is well tolerated in SLE and RA patients in stable condition: in no single case was there a worsening of the main disease after immunization. Furthermore, we concluded that the patients run a much higher risk of disease exacerbation as a result of viral or bacterial infections if not vaccinated.

Conclusions

We believe that influenza vaccine is indicated for SLE and RA patients in stable condition. However, this decision has to be made individually, on a patient-by-patient basis. We plan to continue our study with the goal of formulating a better protocol for clinical practice.

References


Submit your manuscripts at http://www.hindawi.com